HomeCompareDCPH vs PEP

DCPH vs PEP: Dividend Comparison 2026

DCPH yields 7.82% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $108.4K in total portfolio value· pulled ahead in Year 6
10 years
DCPH
DCPH
● Live price
7.82%
Share price
$25.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.6K
Annual income
$1,282.05
Full DCPH calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — DCPH vs PEP

📍 PEP pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCPHPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCPH + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCPH pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCPH
Annual income on $10K today (after 15% tax)
$664.32/yr
After 10yr DRIP, annual income (after tax)
$1,089.74/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, PEP beats the other by $51,504.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCPH + PEP for your $10,000?

DCPH: 50%PEP: 50%
100% PEP50/50100% DCPH
Portfolio after 10yr
$87.7K
Annual income
$31,578.86/yr
Blended yield
35.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

DCPH
Analyst Ratings
13
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$26.32
+2.9% upside vs current
Range: $25.00 — $30.00
Altman Z
7.4
Piotroski
3/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCPH buys
0
PEP buys
0
No recent congressional trades found for DCPH or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCPHPEP
Forward yield7.82%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$33.6K$141.9K
Annual income after 10y$1,282.05$61,875.67
Total dividends collected$10.4K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$26.32$172.43

Year-by-year: DCPH vs PEP ($10,000, DRIP)

YearDCPH PortfolioDCPH Income/yrPEP PortfolioPEP Income/yrGap
1$11,482$781.56$10,849$509.42+$633.00DCPH
2$13,124$838.64$11,969$750.47+$1.2KDCPH
3$14,938$895.89$13,500$1,124.14+$1.4KDCPH
4$16,937$953.05$15,680$1,721.66+$1.3KDCPH
5$19,133$1,009.87$18,929$2,715.34+$204.00DCPH
6← crossover$21,538$1,066.15$24,023$4,450.80$2.5KPEP
7$24,167$1,121.67$32,510$7,669.92$8.3KPEP
8$27,035$1,176.26$47,709$14,093.60$20.7KPEP
9$30,158$1,229.77$77,415$28,083.48$47.3KPEP
10$33,551$1,282.05$141,922$61,875.67$108.4KPEP

DCPH vs PEP: Complete Analysis 2026

DCPHStock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Full DCPH Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this DCPH vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCPH vs SCHDDCPH vs JEPIDCPH vs ODCPH vs KODCPH vs MAINDCPH vs MODCPH vs PMDCPH vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.